These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 32469607

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Morin hydrate loaded solid lipid nanoparticles: Characterization, stability, anticancer activity, and bioavailability.
    Karamchedu S, Tunki L, Kulhari H, Pooja D.
    Chem Phys Lipids; 2020 Nov; 233():104988. PubMed ID: 33035545
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
    Chougule M, Sirvi A, Saini V, Kashyap M, Sangamwar AT.
    Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
    Gajera BY, Shah DA, Dave RH.
    Int J Pharm; 2019 Mar 25; 559():348-359. PubMed ID: 30721724
    [Abstract] [Full Text] [Related]

  • 8. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C, Dang Y, Lin G, Yao Y, Li G, Ji G, Shen H, Xie Y.
    Int J Pharm; 2014 Dec 30; 477(1-2):251-60. PubMed ID: 25445518
    [Abstract] [Full Text] [Related]

  • 9. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR, Bari SB.
    Recent Pat Drug Deliv Formul; 2018 Dec 30; 12(3):162-169. PubMed ID: 30003863
    [Abstract] [Full Text] [Related]

  • 10. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
    Guo JJ, Yue PF, Lv JL, Han J, Fu SS, Jin SX, Jin SY, Yuan HL.
    Int J Pharm; 2013 Jan 30; 441(1-2):227-33. PubMed ID: 23220096
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
    Alshweiat A, Csóka I, Tömösi F, Janáky T, Kovács A, Gáspár R, Sztojkov-Ivanov A, Ducza E, Márki Á, Szabó-Révész P, Ambrus R.
    Int J Pharm; 2020 Apr 15; 579():119166. PubMed ID: 32084574
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development of nanosuspension formulation for oral delivery of quercetin.
    Sun M, Gao Y, Pei Y, Guo C, Li H, Cao F, Yu A, Zhai G.
    J Biomed Nanotechnol; 2010 Aug 15; 6(4):325-32. PubMed ID: 21323105
    [Abstract] [Full Text] [Related]

  • 15. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
    Parmar K, Shah J.
    Curr Drug Deliv; 2021 Aug 15; 18(8):1148-1161. PubMed ID: 33438540
    [Abstract] [Full Text] [Related]

  • 16. Fabrication of Ibrutinib Nanosuspension by Quality by Design  Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
    Rangaraj N, Pailla SR, Chowta P, Sampathi S.
    AAPS PharmSciTech; 2019 Oct 28; 20(8):326. PubMed ID: 31659558
    [Abstract] [Full Text] [Related]

  • 17. Recent Advances in Nanosuspension Technology for Drug Delivery.
    Arora D, Khurana B, Rath G, Nanda S, Goyal AK.
    Curr Pharm Des; 2018 Oct 28; 24(21):2403-2415. PubMed ID: 29788880
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
    Elsebay MT, Eissa NG, Balata GF, Kamal MA, Elnahas HM.
    Curr Pharm Des; 2023 Oct 28; 29(29):2297-2312. PubMed ID: 37694786
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.